A study of the drug topiramate to slow the progress of unknown nerve damage

What we are studying

The purpose of this study is to learn if the drug topiramate slows the progression of Cryptogenic Sensory Peripheral Neuropathy (CSPN) (also known as "idiopathic neuropathy"), and improves quality of life. Idiopathic neuropathy is nerve damage that interferes with the functioning of the peripheral nervous system and the cause of the nerve damage is unknown. As part of this study, we will use a number of assessments and questionnaires to determine if topiramate improves symptoms of CSPN.

Who is Eligible

  • All Genders
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • People diagnosed with Cryptogenic Sensory
  • Peripheral Neuropathy (CSPN) and Metabolic Syndrome.

What is involved

  • Informed Consent Review
  • Review of Medical History
  • Physical Examinations
  • Study Visits and Consultations
  • Surveys/Questionnaires
  • Laboratory and Imaging Tests
  • Specimen Sample Collection
  • Use of Study Treatments or Placebo
  • Use of Study Health Plans
  • After Study Follow-Up Activities

Compensation

Compensation will be discussed with each potential participant.

Contact Information

Study Coordinator
Summer Harris
Email
sdharris@wakehealth.edu
Phone
(336) 716-3919
Principal Investigator
James B. Caress, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.